Kevin DeJong, an associate in Goodwin’s Litigation Group, focuses his practice on intellectual property litigation. Mr. DeJong has advised clients in a variety of intellectual property-related litigations in the pharmaceutical, medical device and software industries.




Mr. DeJong's representative matters include:

  • Teva Pharmaceuticals USA et al. v. Sandoz, Inc. et al. and Mylan Pharmaceuticals Inc. et al. (S.D.N.Y.). Represented patent owner in Hatch-Waxman dispute regarding generic version of Copaxone, a complex mixture of polypeptides. Was part of trial team that obtained decision in favor of Teva finding all claims infringed, valid, and enforceable.
  • Teva Pharmaceuticals USA et al. v. Sandoz, Inc. et al. and Mylan Pharmaceuticals Inc. et al. (S.D.N.Y.). Represented patent owner in patent litigation involving techniques to measure the molecular weight of complex mixtures of polypeptides.
  • Momenta Pharmaceuticals v. Teva Pharmaceuticals (D. Mass). Represented Teva in patent litigation related to methods of evaluating low molecular weight heparins.
  • iHance, Inc. v. Eloqua Ltd. (E.D. Va.). Represented Eloqua in patent litigation involving technology for monitoring email and website behavior of email recipients.
  • Abbott Point of Care, Inc. v. Epocal, Inc. (N.D. Ala.). Represented Epocal in patent litigation dispute related to point-of-care blood testing diagnostic devices. Was part of trial team that obtained jury verdict in Epocal’s favor in finding no infringement.
  • X-ray Optical Systems v. Innov-X (N.D.N.Y.). Represented Innov-X in patent ownership dispute relating to x-ray optics technology.
  • Asentinel LLC v. The Info Group, Inc. et al. (W.D. Tenn.). Represented Veramark in patent litigation involving technology used in analyzing telecommunications invoices.
Professional Activities

Mr. DeJong is a member of the Boston Intellectual Property Inn of Court, the Boston Bar Association and the New Hampshire Bar Association. Mr. DeJong also serves as an editor of the firm’s biosimilars blog,

Professional Experience

Prior to joining Goodwin, Mr. DeJong worked as an engineer in the pharmaceutical and biotechnology industry. He has extensive experience in pharmaceutical and biotech manufacturing, process development and scale-up, and equipment design.


While attending law school, Mr. DeJong served as Editor-in-Chief of the 49th Volume of IDEA: The Intellectual Property Law Review.

In The News







J.D., 2009
University of New Hampshire School of Law

(magna cum laude)

B.S., Chemical Engineering, 1999
Northwestern University



U.S. Patent and Trademark Office (USPTO)
New Hampshire


U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the District of Massachusetts
U.S. District Court of New Hampshire
Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers